BREYANZI 2L setting patient profiles
Jump to section:
Meet Charlotte*
Patient Background1,3
- 60 years of age
- Relapsed HGBCL with MYC and BCL2 and/or BCL6 rearrangements
- Considered eligible for HSCT
- Married interior designer who is heavily involved in her local community
Clinical History1,2
- Response to prior therapy
- Achieved CR with DA-EPOCH-R treatment, but relapsed at 11 months
- Additional information: Double-hit lymphoma
Clinical Stability1
- ECOG PS: 0
- LVEF: 55%
- Renal function: CrCl: 70 mL/min
- Normal bone marrow reserve
- ANC 4 x 109 cells/L, platelets 400 x 109 L
ANC: absolute neutrophil count; CR: complete response; CrCl: creatinine clearance; DA-EPOCH-R: dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; ECOG PS: Eastern Cooperative Oncology Group performance status; HGBCL: high-grade B-cell lymphoma; HSCT: hematopoietic stem cell transplant; LVEF: left ventricular ejection fraction.
* Fictitious patient case. May not be representative of the general population.
Meet Laurie*
Patient Background1,3
- 68 years of age
- Relapsed DLBCL NOS
- Considered eligible for HSCT
- Former social worker who is enjoying her retirement
Clinical History1,2
- Response to prior therapy
- Refractory to R-CHOP
Clinical Stability1
- ECOG PS: 1
- LVEF: 55%
- Renal function: CrCl: 60 mL/min
- Normal bone marrow reserve
CR: complete response; CrCl: creatinine clearance; DLBCL: diffuse large B-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; HSCT: hematopoietic stem cell transplant; LVEF: left ventricular ejection fraction; NOS: not otherwise specified; R-CHOP: rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone.
* Fictitious patient case. May not be representative of the general population.
Meet Luke*
Patient Background1,3
- 52 years of age
- Relapsed DLBCL NOS
- Considered eligible for HSCT
- Published author and motivational speaker who likes to take his dog out for walks
Clinical History1,2
- Response to prior therapy
- Refractory disease to 4 cycles of R-CHOP
- Additional information: 1 extranodal site
Clinical Stability1
- ECOG PS: 1
- LVEF: 45%
- Renal function: CrCl: 55 mL/min
CR: complete response; CrCl: creatinine clearance; DLBCL: diffuse large B-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; HSCT: hematopoietic stem cell transplant; LVEF: left ventricular ejection fraction; NOS: not otherwise specified; R-CHOP: rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone.
* Fictitious patient case. May not be representative of the general population.
Interested in BREYANZI 3L+ setting patient profiles?
Learn more about the
safety profile of
BREYANZI
Explore the efficacy
profile of BREYANZI
Discover the Patient
Support Program for
BREYANZI
3L: third-line.
References:
1. BREYANZI Product Monograph. Bristol-Myers Squibb Company.
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 23, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.
3. Abramson JS, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675-1684.